Table 1.
Frequency of Anorexiaa with TKI Treatment
| TKI | Phase | Cancer Type | Control Group | Number of Patients, TKI/Control | TKI Group Frequency of Anorexia, % | Control Group Frequency of Anorexia, % | Reference | ||
|---|---|---|---|---|---|---|---|---|---|
| All Grade | Grade 3 or 4 | All Grade | Grade 3 or 4 | ||||||
| Sunitinib | 3 | RCC | Nivolumab plus ipilumumab | 535/547 | 25 | <1 | 14 | 1 | Motzer et al41 |
| 3 | RCC | INF-α | 375/360 | 44 | 2 | 39 | 2 | Motzer et al42 | |
| 3 | pNET | Placebo | 83/82 | 22 | 2 | 21 | 1 | Raymond et al43 | |
| 3 | GIST | Placebo | 202/102 | 19 | 0 | 6 | 1 | Demetri et al44 | |
| Sorafenib | 3 | RCC | Placebo | 451/451 | 16 | <1 | 13 | 1 | Escudier et al45 |
| 3 | HCC | Placebo | 297/302 | 14 | <1 | 3 | 1 | Llovet et al46 | |
| 3 | DTC | Placebo | 207/209 | 31.9 | 2.4 | 4.8 | 0 | Brose et al47 | |
| Pazopanib | 3 | RCC | Sunitinib | 554/548 | 37 | 1 | 37 | 3 | Motzer et al48 |
| Axitinib | 3 | RCC | Sorafenib | 189/96 | 29 | 2 | 19 | 0 | Hutson et al49 |
| Regorafenib | 3 | GIST | Placebo | 132/66 | 20.5 | 0 | 7.6 | 0 | Demetri et al50 |
| 3 | CRC | Placebo | 500/253 | 30 | 3 | 15 | 3 | Grothey et al51 | |
| 3 | HCC | Placebo | 374/193 | 31 | 3 | 15 | 2 | Bruix et al52 | |
| Cabozantinib | 3 | RCC | Everolimus | 331/322 | 46 | 2 | 34 | <1 | Choueiri et al53 |
| 3 | MTC | Placebo | 214/109 | 45.8 | 4.7 | 15.6 | 0.9 | Elisei et al54 | |
| 3 | HCC | Placebo | 467/237 | 48 | 6 | 18 | <1 | Abou-Alfa et al55 | |
| Lenvatinib | 3 | DTC | Placebo | 261/131 | 50.2 | 5.4 | 11.5 | 0 | Schlumberger et al56 |
| 3 | HCC | Sorafenib | 476/475 | 34 | 5 | 27 | 1 | Kudo et al57 | |
| 2 | RCC | Everolimus | 52/50 | 58 | 4 | 18 | 0 | Motzer et al58 | |
Notes: aIncludes decreased appetite.
Abbreviations: CRC, colorectal cancer; DTC, differentiated thyroid carcinoma; GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; INF-α, interferon alpha; MTC, medullary thyroid cancer; pNET, pancreatic neuroendocrine tumor; RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor.